Jessica Mathews

Jessica O. Matthews is a Nigerian-American entrepreneur and CEO of Uncharted, a company focused on creating sustainable infrastructure with the goal of universal access. Founded in 2011, Uncharted aims to reduce development costs globally. The company has gained support from high-profile investors such as Disney, Issa Rae, Magic Johnson Enterprises, and Chris Paul. Matthews believes that these investors are invested in Uncharted's mission because they share the same goal of advancing their communities. As Uncharted evolves, Matthews ensures she keeps up with the ever-changing tech world and is a proponent of sustainable development aided by AI. She hopes to see the Black community use its influence to make an impact in the AI space, similar to its influence in music and fashion.

Biography:  https://finance.yahoo.com/news/uncharted-ceo-jessica-o-matthews-185630609.html

68%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

0%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

5%

Examples:

  • Only one in four U.S. patients were still taking Wegovy or Ozempic two years later according to an analysis of U.S. pharmacy claims.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1 Drugs: A Step Forward in Obesity Care but Not a Silver Bullet

GLP-1 Drugs: A Step Forward in Obesity Care but Not a Silver Bullet

Broke On: Wednesday, 10 July 2024 GLP-1 drugs like Ozempic and Wegovy offer weight loss benefits and health improvements, but they don't address the systemic issues in obesity care. A survey by Verywell Health revealed that many people face barriers to respectful care. Dr. Fatima Cody Stanford's research revolutionized obesity medicine with approved diabetes drugs for treating obesity. However, these drugs are not a long-term solution for weight loss or addressing underlying issues contributing to obesity.